Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities.  Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.

Biotechnology

Symphogen

Christophe Thurieau

Heidi Rønnest

Pia Holm Olesen

Malin Carlsson

Michael Herbst

Mads Laustsen

Ivan Horak

Dorthe Sandager Bilde

Rikke Bolding Jensen

Carsten Helle Højgaard

Michael Rasmussen

Claus Haase

The Leadership Team at Symphogen is responsible for setting the strategic direction and overseeing the execution of the company's clinical-stage antibody oncology initiatives. Comprising key executives and principal scientists, this team drives innovation in monoclonal antibody research and development, ensures alignment with precision medicine goals, and fosters collaboration across departments to enhance pipeline performance and operational efficiency. Their leadership is pivotal in navigating regulatory landscapes, managing resources, and advancing Symphogen's mission to improve patient outcomes through targeted therapeutic solutions.

Leadership Team

Scientific Team

Laboratory Team

Leadership Team

About

Team members

Other teams at Symphogen

Scientific Team

Laboratory Team